An article Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors WOS:000468145300011 published article about DRUG-RESISTANCE; BIOLOGICAL EVALUATION; SIGNALING PATHWAYS; IN-VITRO; CANCER; KINASE; DERIVATIVES; DESIGN; 3-KINASE; MEK in [Geng, Aixin; Cui, Hao; Zhang, Liyuan; Chen, Xin; Li, Hongmei; Zhu, Yong] China Pharmaceut Univ, Sch Sci, Dept Organ Chem, 639 Longmian Ave, Nanjing 211198, Jiangsu, Peoples R China; [Lu, Tao] China Pharmaceut Univ, Sch Sci, Lab Mol Design & Drug Discovery, 639 Longmian Ave, Nanjing 211198, Jiangsu, Peoples R China; [Lu, Tao] China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjiaxiang, Nanjing 210009, Jiangsu, Peoples R China; [Chen, Xin] Northwest A&F Univ, Coll Sci, Shanxi Key Lab Nat Prod & Chem Biol, Yangling 712100, Peoples R China in 2019.0, Cited 25.0. The Name is 4-Nitrobenzoic acid. Through research, I have a further understanding and discovery of 62-23-7. Quality Control of 4-Nitrobenzoic acid
Histone deacetylase (HDAC) inhibitors as an important epigenetic therapeutic strategy affect signaling networks and act synergistically with kinase inhibitors for the treatment of cancer. Herein we presented a series of novel phenoxybenzamide analogues with inhibition of Raf and HDAC. Among them, compound 10e showed potent antiproliferative activities against Hepg2 and MDA-MB-468 in cellular assays. This work may lay the foundation for developing novel dual Raf/HDAC inhibitors as potential anticancer therapeutics.
Welcome to talk about 62-23-7, If you have any questions, you can contact Geng, AX; Cui, H; Zhang, LY; Chen, X; Li, HM; Lu, T; Zhu, Y or send Email.. Quality Control of 4-Nitrobenzoic acid
Reference:
Phthalazine – Wikipedia,
,Phthalazine | C8H6N2 – PubChem